0.45
+1.12%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Starpharma Holdings
Its shares trade on ASX under the ticker SPL.AX. It has been listed since 28 September 2000. In the fiscal year to 30 June 2026, it reported revenue of A$12.1m and a net loss of A$7.5m. At that date it held total assets of A$19.0m and shareholders' equity of A$13.8m.
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-09-28. The firm utilizes dendrimers, which is a type of synthetic nanoscale polymer that is regular in size and structure and suited to pharmaceutical and medical uses. The Company’s development programs, including VivaGel portfolio and DEP drug delivery. The Company’s DEP drug delivery, which includes DEP docetaxel, DEP cabazitaxel, DEP irinotecan and Targeted-DEP. The company develops and commercializes dendrimer nanotechnology across various applications, including sexual health, drug delivery for pharmaceuticals, animal health, coatings and inks, crop protection, diagnostics and research reagents, cosmetics and water treatment. Its products are based on VivaGel (SPL7013, astodrimer sodium), a dendrimer, which has antimicrobial properties. The company has both partnered and internal programs in drug delivery.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Sept 2000
- Employees
- 48
- Website
- starpharma.com ↗
Leadership
Pay as last reported
- Mr. Robert ThomasIndependent Non-Executive Chairman of the BoardA$136,948
- Ms. Cheryl MaleyChief Executive Officer, Managing Director, Director, since 2024A$475,764
- Mr. Justin CahillChief Financial Officer, Company SecretaryA$464,158
- Dr. Jeremy PaullVice President - Development and Regulatory Affairs, since 2005A$260,683
- Dr. A Tony EglezosVice President - Business DevelopmentA$249,700
- Dr. Russell BasserIndependent Non-Executive DirectorA$77,040
- Ms. Lynda ChengIndependent Non-Executive DirectorA$88,539
- Dr. Jeff DaviesIndependent Non-Executive DirectorA$77,040
- Mr. David McintyreIndependent Non-Executive DirectorA$83,039
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 39
- Social
- 99
- Governance
- 35
- Direct emissions (scope 1)
- 15.04 t
- Energy emissions (scope 2)
- 357.18 t
- Women in the workforce
- 55%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Starpharma Holdings Ltd has several strengths that contribute to its success:
- Starpharma develops and commercializes pharmaceutical products based on its proprietary dendrimer technology. The company's innovative approach allows for the development of highly effective drug delivery systems and unique therapeutic applications.
- Starpharma's dedicated R&D team continuously works on expanding the applications of dendrimers, exploring new drug delivery methods, and enhancing the company's product portfolio. This commitment to innovation positions the company at the forefront of the industry.
- Starpharma has established strategic partnerships with leading pharmaceutical companies, enabling it to access additional resources, expertise, and distribution channels. These partnerships enhance the company's market reach and accelerate product commercialization.
Weaknesses
- Despite its strengths, Starpharma Holdings Ltd faces certain weaknesses:
- The company's reliance on strategic partnerships can create potential vulnerabilities, as it may be subject to the decisions and strategies of its partners. Any changes or terminations in these partnerships could impact Starpharma's operations and financial performance.
- While the company's dendrimer-based products have shown immense potential, Starpharma currently has a relatively limited product portfolio. Overreliance on a limited range of products can make the company vulnerable to changes in market demand or increased competition.
Opportunities
- Starpharma Holdings Ltd can capitalize on the following opportunities:
- The drug delivery market is expanding rapidly, driven by advancements in targeted and controlled drug release technologies. Starpharma's innovative dendrimer-based delivery systems position the company to seize a significant share of this market, particularly in specialized therapeutic areas.
- The global demand for antiviral solutions, fueled by outbreaks such as the COVID-19 pandemic, presents an opportunity for Starpharma. The company's antiviral products, such as SPL7013, have potential applications in various antiviral fields, including personal hygiene, healthcare, and pandemic response.
Threats
- Starpharma Holdings Ltd faces certain threats that could impact its business:
- The pharmaceutical industry is highly regulated, and stringent regulations and compliance requirements can pose challenges for product development, clinical trials, and market approvals. Starpharma needs to navigate these regulatory hurdles effectively to ensure timely product commercialization.
- The biotechnology and pharmaceutical sectors are competitive, with numerous companies vying for market share. Starpharma faces competition from both established players and emerging biotech firms. Sustaining a competitive advantage requires continuous innovation, marketing efforts, and maintaining strong intellectual property protection.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.